Biogen, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
    • Gene Therapy, Cell Therapy
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Biogen Dompé
  • Biogen Idec
  • Conforma Therapeutics
  • Convergence Pharmaceuticals
  • Fumapharm
  • Human Immunology Biosciences (HI-Bio)
  • Nightstar Therapeutics
  • Reata Pharmaceuticals
  • Syntonix Pharmaceuticals
  • Stromedix
See more in Biomedtracker

Latest on Biogen, Inc.

Scrip

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

Patients with early Alzheimer’s disease, caregivers and doctors who may have been reluctant to try Eli Lilly’s Kisunla (donanemab) due to the risk of amyloid-related imaging abnormalities (ARIA) with

Scrip

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By Andy Smith

Casualties Of Risk-Off My time in the City included the management of four UK-listed biotech investment trusts and unit trusts. Investment trusts date back to the mid-1800s and can invest in both priv

Scrip

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on Ju

Pink Sheet

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 
• By Neena Brizmohun

Eisai and Eli Lilly are to appeal against today’s final decision by England’s health technology assessment institute, NICE, to deny funding for their respective Alzheimer’s disease drugs – Leqembi and